Hikma Pharmaceuticals PLC HIK shares shed 2.70% to £20.16 Thursday, on what proved to be an all-around positive trading ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Buy rating on Hikma Pharmaceuticals (HIK – Research Report), ...

Hikma Pharmaceuticals PLC closed 10.00% short of its 52-week high of £23.60, which the company reached on February 13th.

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...

JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a report released on Friday morning, Marketbeat.com reports. Separately, Berenberg ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

today announced that it has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. (Hikma) resolving patent litigation related to Axsome’s product Sunosi ® (solriamfetol).

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Hikma was founded in Jordan and is the second largest drugmaker in the Middle East and north Africa by sales, after French pharmaceutical company Sanofi. Mishlawi said weight loss drugs are very ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...